ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Genetic landscape of cancer: mechanisms, key genes, and therapeutic implications.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Multiplex networks-based directed graph neural network for cancer driver gene identification.PLoS computational biology · 2026Article
- Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.Biomarker research · 2026Review
- Deuterium Concentration as a Dual Regulator: Depletion and Enrichment Elicit Divergent Transcriptional Responses in A549 Lung Adenocarcinoma Cells.International journal of molecular sciences · 2026Article
- Identification and management of genetic susceptibility to cancer: UK perspective.BMJ oncology · 2026Review
- Therapeutic Targets for Overcoming BCR::ABL1 Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.Oncology research · 2026Review
- Recent Advances in Anti-Cancer Drugs.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a complex and heterogeneous disease driven by a multitude of genetic alterations, including mutations, chromosomal rearrangements, and epigenetic modifications. Advances in genomic technologies have significantly enhanced our understanding of the genetic landscape of cancer, enabling the identification of key oncogenes, tumor suppressor genes, and DNA repair mechanisms that influence tumor progression. This review examines the molecular mechanisms underlying cancer development, focusing on the roles of mutations in genes such as TP53, KRAS, and EGFR. Furthermore, it explores the implications of genomic instability, tumor microenvironment interactions, and the emergence of precision medicine in oncology. The integration of next-generation sequencing and bioinformatics has facilitated the discovery of novel therapeutic targets, paving the way for personalized treatment strategies. Despite these advancements, challenges remain, including treatment resistance, tumor heterogeneity, and ethical considerations in genetic research. Addressing these complexities requires a multidisciplinary approach that combines molecular biology, bioinformatics, and clinical research. This review synthesizes current knowledge on cancer genetics, highlighting its importance in developing targeted therapies and enhancing patient outcomes.
Indexed as
Identifiers
40820071What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.